This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LUMO Lumos Pharma (LUMO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Lumos Pharma Stock (NASDAQ:LUMO) 30 days 90 days 365 days Advanced Chart Get Lumos Pharma alerts:Sign Up Key Stats Today's Range$4.34▼$4.3450-Day Range$4.30▼$4.4152-Week Range$1.46▼$4.58VolumeN/AAverage Volume100,335 shsMarket Capitalization$37.54 millionP/E RatioN/ADividend YieldN/APrice Target$4.25Consensus RatingBuy Company Overview Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas. Read More Receive LUMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LUMO Stock News HeadlinesLumos House is Back in Austin: Exclusive Events for Founders and BuildersMarch 4, 2025 | reuters.comLumos Pharma Completes Merger and Delisting ProcessDecember 12, 2024 | tipranks.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.September 16 at 2:00 AM | Porter & Company (Ad)Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos PharmaDecember 12, 2024 | globenewswire.comLumos Pharma reports sustained growth in PGHD trialsNovember 23, 2024 | uk.investing.comLumos announces new analyses of data from OraGrowtH210, OraGrowtH212 trialsNovember 21, 2024 | markets.businessinsider.comHold Rating on Lumos Pharma Amid Financial Challenges and Strategic Merger with Double Point VenturesNovember 10, 2024 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMONovember 6, 2024 | globenewswire.comSee More Headlines LUMO Stock Analysis - Frequently Asked Questions How were Lumos Pharma's earnings last quarter? Lumos Pharma, Inc. (NASDAQ:LUMO) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.34. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.50 million. Lumos Pharma had a negative net margin of 1,583.49% and a negative trailing twelve-month return on equity of 233.03%. What other stocks do shareholders of Lumos Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lumos Pharma investors own include uniQure (QURE), Clean Energy Fuels (CLNE), ACADIA Pharmaceuticals (ACAD), Bicycle Therapeutics (BCYC), Curaleaf (CURLF), Paycom Software (PAYC) and Vale (VALE). Company Calendar Last Earnings11/07/2024Today9/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LUMO CIK1126234 Webwww.lumos-pharma.com Phone(512) 215-2630Fax515-296-3520Employees30Year FoundedN/APrice Target and Rating Average Price Target for Lumos Pharma$4.25 High Price Target$4.25 Low Price Target$4.25 Potential Upside/Downside-2.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($4.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.03 million Net Margins-1,583.49% Pretax Margin-1,583.49% Return on Equity-233.03% Return on Assets-129.88% Debt Debt-to-Equity RatioN/A Current Ratio2.66 Quick Ratio2.66 Sales & Book Value Annual Sales$2.21 million Price / Sales17.02 Cash FlowN/A Price / Cash FlowN/A Book Value$3.45 per share Price / Book1.26Miscellaneous Outstanding Shares8,649,000Free Float6,452,000Market Cap$37.54 million OptionableNot Optionable Beta0.74 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:LUMO) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lumos Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lumos Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
